Winglad HMG 75 Injection contains Menotrophin 75 IU, a purified preparation of human menopausal gonadotropins comprising follicle-stimulating hormone (FSH) and luteinizing hormone (LH). It is indicated for the treatment of infertility in both male and female patients. In females, Winglad HMG 75 is used to stimulate follicular development in anovulatory or oligo-ovulatory women undergoing assisted reproductive technologies such as in vitro fertilization (IVF) or intrauterine insemination (IUI). It promotes the maturation of ovarian follicles by mimicking the natural gonadotropin activity, thereby facilitating ovulation. In males, it is employed to stimulate spermatogenesis in cases of hypogonadotropic hypogonadism where endogenous gonadotropin secretion is insufficient. The injection should be administered under the supervision of a healthcare professional experienced in infertility treatment, with dosage individualized based on patient response and monitored through serum hormone levels and ultrasound assessment of follicular growth. Common adverse effects may include ovarian hyperstimulation syndrome (OHSS), injection site reactions, and mild gastrointestinal disturbances. Winglad HMG 75 Injection is contraindicated in patients with primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, or hypersensitivity to gonadotropins. Proper patient selection and monitoring are essential to optimize therapeutic outcomes and minimize risks.